Patents by Inventor Yongrong ZHANG

Yongrong ZHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein inhibitors of clostridium difficile toxin b
    Patent number: 12161691
    Abstract: In an embodiment, the present disclosure pertains to a method of treating or preventing C. difficile infections. In some embodiments, the method includes administering an antitoxin to a subject in need thereof. In some embodiments, the antitoxin includes a designed ankyrin repeat protein (DARPin). In an additional embodiments, the present disclosure pertains to a composition including an antitoxin for treating or preventing C. difficile infections. In some embodiments, the anti-toxin includes a DARPin. In some embodiments, the anti-toxin is a monomeric or dimeric DARPin for the neutralization of Clostridium difficile toxin B (TcdB).
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: December 10, 2024
    Assignees: The Texas A&M University System, University of Maryland, Baltimore
    Inventors: Zhilei Chen, Rudo Simeon, Ana M. Chamoun-Emanuelli, Zeyu Peng, Hanping Feng, Hua Yu, Yongrong Zhang
  • Humanized tetra-specific octavalent antibody against clostridium difficile toxin A and B
    Patent number: 12077575
    Abstract: Novel, antibody-based binding agents derived from camelid VHH and human immunoglobulins are described. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include humanized VHH peptide monomers, linked groups of humanized VHH peptide monomers, humanized VHH peptide monomers joined to antibody Fc domains, and humanized VHH peptide monomers joined to IgG antibodies.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: September 3, 2024
    Assignees: FZATA, INC., UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Hanping Feng, Yongrong Zhang, Zhiyong Yang, Hua Yu, Yifan Zhang
  • HUMANIZED TETRA-SPECIFIC OCTAVALENT ANTIBODY AGAINST CLOSTRIDIUM DIFFICILE TOXIN A AND B
    Publication number: 20220235120
    Abstract: Novel, antibody-based binding agents derived from camelid VHH and human immunoglobulins are described. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include humanized VHH peptide monomers, linked groups of humanized VHH peptide monomers, humanized VHH peptide monomers joined to antibody Fc domains, and humanized VHH peptide monomers joined to IgG antibodies.
    Type: Application
    Filed: June 3, 2020
    Publication date: July 28, 2022
    Applicants: University of Maryland, Baltimore, FZata, Inc.
    Inventors: Hanping Feng, Yongrong Zhang, Zhiyong Yang, Hua Yu, Yifan Zhang
  • PROTEIN INHIBITORS OF CLOSTRIDIUM DIFFICILE TOXIN B
    Publication number: 20220226430
    Abstract: In an embodiment, the present disclosure pertains to a method of treating or preventing C. difficile infections. In some embodiments, the method includes administering an antitoxin to a subject in need thereof. In some embodiments, the antitoxin includes a designed ankyrin repeat protein (DARPin). In an additional embodiments, the present disclosure pertains to a composition including an antitoxin for treating or preventing C. difficile infections. In some embodiments, the anti-toxin includes a DARPin. In some embodiments, the anti-toxin is a monomeric or dimeric DARPin for the neutralization of Clostridium difficile toxin B (TcdB).
    Type: Application
    Filed: May 11, 2020
    Publication date: July 21, 2022
    Inventors: Zhilei Chen, Rudo Simeon, Ana M. Chamoun-Emanuelli, Zeyu Peng, Hanping Feng, Hua Yu, Yongrong Zhang
  • Tetra-specific, octameric binding agents and antibodies against toxin A and toxin B for treatment of infection
    Patent number: 10961299
    Abstract: Novel, antibody-based binding agents derived from human and camelid immunoglobulins are described. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: March 30, 2021
    Assignee: University of Maryland, Baltimore
    Inventors: Hanping Feng, Yongjun Guan, Yongrong Zhang, Zhiyong Yang, Lianfa Shi
  • TETRA-SPECIFIC, OCTAMERIC BINDING AGENTS AND ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXIN A AND TOXIN B FOR TREATMENT OF C. DIFFICILE INFECTION
    Publication number: 20180244760
    Abstract: Novel, antibody-based binding agents derived from human and camelid immunoglobulins are described. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.
    Type: Application
    Filed: February 5, 2016
    Publication date: August 30, 2018
    Applicant: University of Maryland, Baltimore
    Inventors: Hanping FENG, Yongjun GUAN, Yongrong ZHANG, Zhiyong YANG, Lianfa SHI